аЯрЁБс>ўџ ўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ l ЩсСПРт\pThe Free Software Foundation Bфœ=PF0*8X@"Зк1Д Helvetica1ДCourier1Д Courier New1ДМ Courier New1Д Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)рѕџ Р рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР р Р р+ѕџ јР р)ѕџ јР р,ѕџ јР р*ѕџ јР р ѕџ јР р аˆ ~~Пр иˆ ~~Пр#иˆ ~~Пр"иˆ ~~Пр иˆ ~~Пр8#мˆ ~~Пр3#мˆ ~~Пр9#мˆ ~~П“€џ“€џ“€џ“€џ“€џ“€џ’т8џџџџџџџџџџџџ€€€€€€€€€РРР€€€™™џ™3fџџЬЬџџffџ€€fЬЬЬџ€џџџџџџ€€€€€џЬџЬџџЬџЬџџ™™Ьџџ™ЬЬ™џџЬ™3fџ3ЬЬ™ЬџЬџ™џfff™–––3f3™f333™3™3f33™ЧЧЧ…LTABLE OF CONTENTS…&^License Agreement with the Popu…"DILUTION… , PROSPECTUS l Щ 6ˆЩ  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?ф!License Agreement with the Popu DILUTION PROSPECTUSU } ѓ2} $ } ч} $ 6ссссссссс с с с с сссссссссссссссссссTherapeuticsMD, Inc. 424B5 07/31/2018TABLE OF CONTENTS Prospectus Supplement  Page   (  About this Prospectus Supplement   S-iii % Prospectus Supplement Summary   S-1   Risk Factors   S-12 2*Cautionary Statement About Forward-Looking S-27 InformationUse of Proceeds S-29Dilution S-30Plan of Distribution S-31 Legal Matters S-32Experts S-32+#Where You Can Find More Information S-32,$Incorporation of Certain Information S-32 by Reference ProspectusAbout this Prospectus ii Risk Factors~ "Forward-Looking Statements~   Our Company~ *"Ratio of Earnings to Fixed Charges~ зD­ lрџЯџЙџ­џџ„џxџlџ0џчўЯўnўўЦ§\§E§іќЎќZќ ќЦћcћџњчњЯњ‰њqњњдљ|љ с!с"с#с$с%с&с'с(с)с*с+с,с-с.с/с0с1с2с3с4с5с Dilution  ~  !Use of Proceeds!!~ !!#"Description of Common Stock""~ ""&#Description of Preferred Stock##~ #&#&$Description of Debt Securities$$~ $6$(% Description of Depositary Shares%%~ %f%&Description of Warrants&&~ &r&)'!Description of Purchase Contracts''~ '~'(Description of Units((~ (‚(0)(Certain Provisions of Nevada Law and Our))~ )Š)*Charter and Bylaws%+Legal Ownership of Securities++~ +–+,Plan of Distribution,,~ ,І,- Legal Matters--~ -В-.Experts..~ .В.+/#Where You Can Find More Information//~ /В/,0$Incorporation of Certain Information00~ 0Ж01 by Reference2$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/з0љЄКџmџџИў\ўў§Љ§J§јќ’ќtќќЧћ|ћ7ћжњtњ\њPњ(њ=PF0*8X> Ж@х"554433  l Щ !  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?фTABLE OF CONTENTS DILUTION PROSPECTUSU } ’0} $ } ѓ} $ ссссссссс с с с с ссссссTherapeuticsMD, Inc. 424B5 07/31/20185-License Agreement with the Population Council Annual Net Sales   Royalty Rate + #Less than or equal to $50.0 million  ~  %0 (Greater than $50.0 million and less than  ~ * %" or equal to $150.0 million# Greater than $150.0 million  ~ > %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/з*ІhрџЯџЙџ­џtџhџ\џPџџШўfўџ§й§§s§g§?§=PF0*8X> Ж@х"  l Щ с+  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?фTABLE OF CONTENTS!License Agreement with the Popu PROSPECTUSU } :} $   с с с с с с с с с с с с с с с с с с с с с с с с с с сTherapeuticsMD, Inc. 424B5 07/31/2018DILUTION/ 'Assumed public offering price per share      ЎGсz@ 8 0Net tangible book value per share as of June 30,  Уѕ(\Те?     ~ Š. &Increase per share attributable to new  …ыQИе?       investors/'As adjusted net tangible book value perq= зЃpх?4,share after this offering and the concurrentunderwritten offering3+Dilution per share to new investors in thisffffff@offering$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/з:]рџЯџЙџ­џ™џџџuџ џ|ўц§и§L§7§Ыќ>ќќхћyћшњдњhњ\њPњ(њ=PF0*8X> Ж@хB    l Щ $С8і9  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?фTABLE OF CONTENTS!License Agreement with the Popu DILUTIONU } ’0} $ } U} $ $ссссссссс с с с с сссссссссссссссссссTherapeuticsMD, Inc. 424B5 07/31/2018 PROSPECTUS ABOUT THIS PROSPECTUS   ii   RISK FACTORS  ~  " FORWARD-LOOKING STATEMENTS  ~     OUR COMPANY  ~  * "RATIO OF EARNINGS TO FIXED CHARGES  ~  DILUTION~ USE OF PROCEEDS~ #DESCRIPTION OF COMMON STOCK~ &DESCRIPTION OF PREFERRED STOCK~ &&DESCRIPTION OF DEBT SECURITIES~ 6( DESCRIPTION OF DEPOSITARY SHARES~ fDESCRIPTION OF WARRANTS~ r)!DESCRIPTION OF PURCHASE CONTRACTS~ ~DESCRIPTION OF UNITS~ ‚0(CERTAIN PROVISIONS OF NEVADA LAW AND OUR~ ŠCHARTER AND BYLAWS%LEGAL OWNERSHIP OF SECURITIES~ –PLAN OF DISTRIBUTION~ І LEGAL MATTERS~ ВEXPERTS~ В+#WHERE YOU CAN FIND MORE INFORMATION~ В,$INCORPORATION OF CERTAIN INFORMATION~ Ж BY REFERENCEзD‹ lрџЯџЙџ­џ—џ‹џџsџ7џфўšўBўљ§™§S§§­ќQќѕћ—ћBћуњ‘њ+њ њВљ`љљајoј с!с"с#с $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/з э<єџЬџ=PF0*8X> Ж@х##""!! Root Entryџџџџџџџџ РFўџџџBook џџџџџџџџџџџџ _: ўџџџўџџџ§џџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ